|
|
|
|
|
| | Product Pipeline | | Product Portfolio| |
||||
 | ||||
 Click above to view a large image representing our Pharmaceutical Product Continuum. This information is also displayed in chart format below. (image size 158k) | ||||
Pfizer is introducing new pharmaceutical products at an accelerating pace. We introduced 10 new products in the last decade, and added Trovan in 1998. Now we’re on track to launch several waves of new products with significant commercial potential. Further out, we have 55 promising new compounds in early phases of development. | ||||
| Currently Marketed |
Recently Launched |
Undergoing Regulatory Review |
In Advanced Development | |
| Procardia XL (2003) hypertension; angina Diflucan (2004) fungal infections Cardura (2000) hypertension; benign prostatic hyperplasia Norvasc (2007) hypertension; angina Zoloft (2005) depression; obsessive-compulsive disorder; panic disorder Zithromax (2005) bacterial infections Glucotrol XL (2009) diabetes Zyrtec (2007) allergies |
1 Lipitor high cholesterol and triglycerides 2 Aricept Alzheimer’s disease Trovan bacterial infections |
Viagra erectile dysfunction Zeldox schizophrenia Tikosyn (dofetilide) cardiac arrhythmias |
3 Celebra (celecoxib) rheumatoid arthritis; osteoarthritis; pain eletriptan migraine droloxifene prevention and treatment of osteoporosis; treatment of atherosclerosis inhaled insulin diabetes Alond (zopolrestat) prevention of diabetic neuropathy voriconazole serious fungal infections darifenacin irritable bowel syndrome; urinary urge incontinence candoxatril congestive heart failure UK-292,663 fungal infections CJ-11,974 treatment of emesis | |
| In Early Development To help fuel Pfizer’s future growth, we have 55 new chemical entities in early development. |
New Chemical Entities to Treat the Following: Alzheimer’s Disease, Anxiety, Arthritis, Asthma, Benign Prostatic Hyperplasia, Bone Restoration, Cancer, Chronic Heart Failure, Chronic Obstructive Pulmonary Disease, Depression, Diabetes, Diabetic Complications, Emesis, Frailty, Gastrointestinal Disorders, Impotence, Infection, Ischemic Reperfusion, Lipid Modulation, Migraine, Neurogenic Inflammation, Nicotine Addiction, Obesity, Osteoporosis, Pain, Parkinson’s Disease, Sleep Disorders, Stroke, Transplant Rejection, Wound Healing. | |||
| The date in parentheses is the U.S. patent expiration. 1 Discovered and developed by the Parke-Davis Research Division of Warner-Lambert Company. 2 Discovered and developed by Eisai Co., Ltd. 3 Discovered and developed by G.D. Searle & Co., a division of the Monsanto Company. | ||||
| ||||
 |
 |
 |
 | |
| ||||
 |
||||
 |
||||
| Advisory Information for Investors | ||||
| Copyright © 1997, 1998 Pfizer Inc All rights reserved. | ||||
| ||||